tbuckley/cabot-search huggingface dataset:
MA15.01 Strong PD-L1 Expression Predicts Poor Response and de Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients with EGFR Mutation
Authors: S. Su, Z. Dong, X. Zhi, J. Su, Z. Chen, J. Yang, H. Tu, Q. Zhou, W. Zhong, X. Zhang, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment
Authors: S.K. Qin, Z.G. Ren, Z.Q. Meng, Z.D. Chen, X.L. Chai, J.P. Xiong, Y.X. Bai, L. Yang, H. Zhu, W.J. Fang, X.Y. Lin, X.M. Chen, E.X. Li, Y. Xia, J.J. Zou
Journal: Annals of Oncology (2018)
Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC)
Authors: G.H. Williams, A.G. Nicholson, D.R.J. Snead, E. Thunnissen, S. Lantuejoul, P. Cane, K.M. Kerr, M. Loddo, M. Scott, P.W. Scorer, C. Barker
Journal: Annals of Oncology (2018)
P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer
Authors: J.H. Cho, J. Hyeon, Y. Choi, J. Sun, S. Lee, J.S. Ahn, K. Park, M. Ahn
Journal: Journal of Thoracic Oncology (2018)
P3.01-06 Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC
Authors: S. Bhuniya, P. Mohapatra, P. Mishra, S. Patra, M. Panigrahi, G. Pradhan, S. Sahoo, S. Samal
Journal: Journal of Thoracic Oncology (2018)
P1.13-21 Clinical Efficacy and Safety of Apatinib Combined with EGFR - TKIs in Advanced Non-Small Cell Lung Cancer with EGFR - TKIs Resistance
Authors: X. Song, R. Tian, Y. Guo, X. Zhang, W. Guo, H. Zhu, F. Shen, J. Xu, X. Zhang
Journal: Journal of Thoracic Oncology (2018)
Nonmetabolic functions of metabolic enzymes in cancer development
Authors: Sean Lu, Yugang Wang
Journal: Cancer Communications (2018)

Abstract Metabolism is a fundamental biological process composed of a series of reactions catalyzed by metabolic enzymes. Emerging evidence demonstrates that the aberrant signaling in cancer cells induces nonmetabolic functions of metabolic enzymes in many instrumental cellular activities, which involve metabolic enzyme‐mediated protein post‐translational modifications, such as phosphorylation, acetylation, and succinylation. In the most well‐researched literatures, metabolic enzymes phosphorylate proteins rather than their metabolites as substrates. Some metabolic enzymes have altered subcellular localization, which allows their metabolic products to directly participate in nonmetabolic activities. This review discusses how these findings have deepened our understanding on enzymes originally classified as metabolic enzymes, by highlighting the nonmetabolic functions of several metabolic enzymes responsible for the development of cancer, and evaluates the potential for targeting these functions in cancer treatment.
P2.01-106 A Comparative Analysis of Genomic Alterations by Tumor Tissue and Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer
Authors: G. Woo, S.H. Kim, K.J. Suh, Y.J. Kim, J. Chung, B. Lee, N. Kwon, J. Seo, J.S. Lee
Journal: Journal of Thoracic Oncology (2018)
GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis
Authors: William R. Swindell, Krzysztof Bojanowski, Mark S. Kindy, Raymond M. W. Chau, Dorothy Ko
Journal: Translational Neurodegeneration (2018)

Amyotrophic lateral sclerosis (ALS) is currently an incurable disease without highly effective pharmacological treatments. The peptide drug GM604 (GM6 or Alirinetide) was developed as a candidate ALS therapy, which has demonstrated safety and good drug-like properties with a favorable pharmacokinetic profile. GM6 is hypothesized to bolster neuron survival through the multi-target regulation of developmental pathways, but mechanisms of action are not fully understood. This study used RNA-seq to evaluate transcriptome responses in SH-SY5Y neuroblastoma cells following GM6 treatment (6, 24 and 48 h). We identified 2867 protein-coding genes with expression significantly altered by GM6 (FDR < 0.10). Early (6 h) responses included up-regulation of Notch and hedgehog signaling components, with increased expression of developmental genes mediating neurogenesis and axon growth. Prolonged GM6 treatment (24 and 48 h) altered the expression of genes contributing to cell adhesion and the extracellular matrix. GM6 further down-regulated the expression of genes associated with mitochondria, inflammatory responses, mRNA processing and chromatin organization. GM6-increased genes were located near GC-rich motifs interacting with C2H2 zinc finger transcription factors, whereas GM6-decreased genes were located near AT-rich motifs associated with helix-turn-helix homeodomain factors. Such motifs interacted with a diverse network of transcription factors encoded by GM6-regulated genes (STAT3, HOXD11, HES7, GLI1). We identified 77 ALS-associated genes with expression significantly altered by GM6 treatment (FDR < 0.10), which were known to function in neurogenesis, axon guidance and the intrinsic apoptosis pathway. Our findings support the hypothesis that GM6 acts through developmental-stage pathways to influence neuron survival. Gene expression responses were consistent with neurotrophic effects, ECM modulation, and activation of the Notch and hedgehog neurodevelopmental pathways. This multifaceted mechanism of action is unique among existing ALS drug candidates and may be applicable to multiple neurodegenerative diseases.
CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study
Authors: W.-Z. Zhong, Y.-L. Wu, K.-N. Chen, C. Chen, C.-D. Gu, Q. Wang, J. Wang, W. Mao, G.-B. Qiao, Y. Cheng, L. Xu, C.-L. Wang, M.-W. Chen, X.-N. Yang, H.-J. Chen, H.-H. Yang, J.-J. Yang, Q. Zhou
Journal: Annals of Oncology (2018)
Herpetic Whitlow—A Case of Inadvertent Inoculation With Melanoma Viral Therapy
Authors: Jonathan M. Soh, Eva Galka, Mary Gail Mercurio
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study
Authors: F. Morano, S. Corallo, M. Di Bartolomeo, S. Lonardi, C. Cremolini, L. Rimassa, A. Sartore Bianchi, R. Murialdo, A. Zaniboni, V. Adamo, G. Tomasello, M. Tampellini, L. Fanchini, M. Schirripa, M. Clavarezza, F. Petrelli, R. Longarini, S. Cinieri, F.G.M. de Braud, F. Pietrantonio
Journal: Annals of Oncology (2018)
The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer
Authors: F. Ghiringhelli, E. Limagne, M. Thibaudin, L. Nuttin, A. Spill, V. Derangere, V. Cattan, E. Peranzoni, N. Amellal
Journal: Annals of Oncology (2018)
MA10.09 NECPAL 2: A Multicentre Descriptive Study of Primary and Continuous Attention in Palliative Care in Argentina: Lung Cancer Cohort
Authors: C. Gabay, M. Bonet, M. Castro, R. Tranier, S. Sandijian, S. De Lellis, A. Sauri, V. Tripodoro, G. De Simone
Journal: Journal of Thoracic Oncology (2018)
Similar Uptake of 99mTc-MDP and 67Ga-Citrate at the Sites of Metastatic Calcification
Authors: Meng-Ling Chen, Hung-Yi Su
Journal: Clinical Nuclear Medicine (2018)

A 59-year-old woman presented with fever for 2 weeks. The patient had end-stage renal disease and was undergoing dialysis therapy for 10 years. Plain radiographs revealed extensive calcification in the subcutaneous tissues of the shoulders, thighs, and hips. In this case, TC-MDP bone scan detected all sites of subcutaneous metastatic calcification in one sweep. Ga-citrate scintigraphy was also performed and showed similar uptake at the same locations as those revealed by the bone scan, suggesting the existence of an inflammatory process at the sites of metastatic calcification.
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
Authors: Paolo A. Ascierto, Georgina V. Long, Caroline Robert, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Kerry J. Savage, Micaela M. Hernberg, Celeste Lebbé, Julie Charles, Catalin Mihalcioiu, Vanna Chiarion-Sileni, Cornelia Mauch, Francesco Cognetti, Lars Ny, Ana Arance, Inge Marie Svane, Dirk Schadendorf, Helen Gogas, Abdel Saci, Joel Jiang, Jasmine Rizzo, Victoria Atkinson
Journal: JAMA Oncology (2018)

This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors.To compare the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma.This follow-up of a randomized phase 3 trial analyzed 3-year overall survival data from the randomized, controlled, double-blind CheckMate 066 phase 3 clinical trial. For this ongoing, multicenter academic institution trial, patients were enrolled from January 2013 through February 2014. Eligible patients were 18 years or older with confirmed unresectable previously untreated stage III or IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 but without a BRAF mutation.Patients were treated until progression or unacceptable toxic events with nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks) or dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks).Overall survival.At minimum follow-ups of 38.4 months among 210 participants in the nivolumab group (median age, 64 years [range, 18-86 years]; 57.6% male) and 38.5 months among 208 participants in the dacarbazine group (median age, 66 years [range, 25-87 years]; 60.1% male), 3-year overall survival rates were 51.2% (95% CI, 44.1%-57.9%) and 21.6% (95% CI, 16.1%-27.6%), respectively. The median overall survival was 37.5 months (95% CI, 25.5 months-not reached) in the nivolumab group and 11.2 months (95% CI, 9.6-13.0 months) in the dacarbazine group (hazard ratio, 0.46; 95% CI, 0.36-0.59; P < .001). Complete and partial responses, respectively, were reported for 19.0% (40 of 210) and 23.8% (50 of 210) of patients in the nivolumab group compared with 1.4% (3 of 208) and 13.0% (27 of 208) of patients in the dacarbazine group. Additional analyses were performed on outcomes with subsequent therapies. Treatment-related grade 3/4 adverse events occurred in 15.0% (31 of 206) of nivolumab-treated patients and in 17.6% (36 of 205) of dacarbazine-treated patients. There were no deaths due to study drug toxic effects.Nivolumab led to improved 3-year overall survival vs dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma.ClinicalTrials.gov identifier: NCT01721772.
P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus
Authors: S. Singh, E. Bergsland, C. Card, T. Hope, P. Kunz, D. Laidley, B. Lawrence, S. Leyden, M. Michael, L. Modahl, S. Myrehaug, S. Padda, R. Pommier, R. Ramirez, M. Soulen, J. Strosberg, A. Thawer, B. Wei, B. Xu, E. Segelov
Journal: Journal of Thoracic Oncology (2018)
P1.03-10 The Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients
Authors: Q. Zhang, C. Xu, W. Wang, W. Zhuang, Y. Zhu, Z. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Current Status of Living Donor Liver Transplantation in the United States
Authors: Samir Abu-Gazala, Kim M. Olthoff
Journal: Annual Review of Medicine (2018)

Adult-to-adult living donor liver transplantation (LDLT) was introduced in response to the shortage of deceased donor liver grafts. The number of adult living donor transplants is increasing due to improved outcomes and increasing need. Advantages of LDLT include optimization of the timing of transplant, better organ quality, and lower rates of recipient mortality compared to staying on the wait list for deceased donor liver transplant. Donor safety remains the major focus when considering LDLT. Recent advancements have supported the increased use of LDLT to help decrease wait list death and improve long-term survival of transplant recipients.
Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer
Authors: Fuxing Zhou, Xiaoshan Yang, Hang Zhao, Yu Liu, Yang Feng, Rui An, Xiaohui Lv, Jia Li, Biliang Chen
Journal: Theranostics (2018)

Cisplatin resistance significantly affects the survival rate of patients with ovarian cancer.However, the main mechanism underlying cisplatin resistance in ovarian cancer remains unclear.Methods: Immunohistochemistry was used to determine the expression of OGT, OGA and O-GlcNAc in chemoresistant and chemosensitive ovarian cancer tissues.Functional analyses (in vitro and in vivo) were performed to confirm the role of OGT in cisplatin resistance.Autophagy-related proteins were tested by western blot.Transmission electron microscopy and mRFP-GFP-LC3 adenovirus reporter were used for autophagy flux analysis.Immunoprecipitation assay was utilized to detect protein-protein interactions.Results: We found that O-GlcNAc and O-GlcNAc transferase (OGT) levels were significantly lower in chemoresistant ovarian cancer tissues than in chemosensitive tissues, whereas O-GlcNAcase (OGA) levels did not differ.The down-regulation of OGT increased cisplatin resistance in ovarian cancer cells but had no effect on the efficacy of paclitaxel.The down-regulation of OGT improved tumor resistance to cisplatin in a mouse xenograft tumor model.OGT knockdown enhanced cisplatin-induced autophagy, which reduced apoptotic cell death induced by cisplatin, and promoted autolysosome formation.A reduction in O-GlcNAcylated SNAP-29 levels caused by the down-regulation of OGT promoted the formation of the SNARE complex and autophagic flux.Conclusion: Our findings suggest that down-regulation of OGT enhances cisplatin-induced autophagy via SNAP-29, resulting in cisplatin-resistant ovarian cancer.OGT may represent a novel target for overcoming cisplatin resistance in ovarian cancer.
Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: Survival results from a phase II feasibility study (NAVAL)
Authors: Y. Tsutani, Y. Miyata, K. Suzuki, K. Takamochi, F. Tanaka, H. Nakayama, Y. Yamashita, M. Oda, M. Tsuboi, M. Okada
Journal: Annals of Oncology (2018)
Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)
Authors: E. Felip, M. Nishio, S. Orlov, K. Park, C.-J. Yu, C.-M. Tsai, M. Cobo, M. McKeage, W.-C. Su, T. SK Mok, G.V. Scagliotti, D. Spigel, V.Q. Passos, Z. Chen, A.T. Shaw
Journal: Annals of Oncology (2018)
Lower tumor mutational burden (TMB) and hepatic metastases may predict for lack of response to PD-1 blockade in MSI-H metastatic colorectal cancer (MCRC)
Authors: I. Amanam, J. Chao, D. Lim, S. Rahmanuddin, A.B. Schrock, S.M. Ali, C. Lau, D. Chevalier, E. Harris, J. Saluja, C. Wang, M. Fakih
Journal: Annals of Oncology (2018)
Relationship between ring-type dedicated breast PET and tumor-infiltrating lymphocytes in early breast cancer
Authors: S. Sasada, N. Shiroma, E. Suzuki, S. Sueoka, N. Goda, K. Kajitani, A. Emi, N. Masumoto, T. Kadoya, R. Haruta, T. Kataoka, K. Arihiro, M. Okada
Journal: Annals of Oncology (2018)

Background: FDG uptake on PET is related to biological parameters and prognosis in breast cancer. The predominance of stromal tumor-infiltrating lymphocytes (TILs) in breast cancer is a biomarker for prognosis and pathological complete response after neoadjuvant chemotherapy. However, whether whole-body PET (WBPET) and dedicated breast PET (DbPET) can reflect the amount of TILs is unclear. This study investigated the relationship between TILs and maximum standardized uptake value (SUVmax) in WBPET and ring-type DbPET. Methods: A total of 125 invasive breast cancers underwent WBPET and ring-type DbPET and resected specimens were pathologically assessed. The impact on SUVmax on the tumor biological parameters and TILs was retrospectively evaluated. SUVmax was classified as high and low relative to the median values (WBPET-SUVmax: 2.2 and DbPET-SUVmax: 6.0). Results: SUVmax correlated with tumor size, nuclear grade, Ki-67 labeling index, and TILs in both WBPET and DbPET (all P < 0.001). The cut-off values of tumor size, Ki-67 labeling index, and TILs predicting high SUVmax were 20 mm, 20%, and 20%, respectively. In multivariate analysis, the predictive factors for high SUVmax were tumor size and Ki-67 labeling index for WBPET and tumor size and TILs for DbPET. A high SUVmax in DbPET was related to high numbers of TIL tumors after propensity score matching analysis; however, WBPET was not (P = 0.007 and P = 0.624, respectively).Table: 156PLogistic regression analysis for predicting high SUVmax tumor on WBPET and DbPETFactorsUnivariate analysisMultivariate analysisOdds ratioPOdds ratioP<WBPET>Histology_IC-NST6.710.0031.350.655T2–36.18< 0.00113.0< 0.001Nuclear grade 36.48< 0.0012.700.071ER positive0.390.2850.320.404HER2 positive1.620.4860.310.211Ki-67 labeling index ≥ 20%3.030.0053.680.020TILs ≥ 20%1.990.0842.290.144<DbPET>Histology_IC-NST3.180.0031.680.393T2–34.38< 0.0014.81< 0.001Nuclear grade 34.43< 0.0011.820.238ER positive0.980.9290.700.758HER2 positive0.970.8570.530.450Ki-67 labeling index ≥ 20%3.540.0011.390.513TILs ≥ 20%7.50< 0.0016.98< 0.001 Open table in a new tab Conclusions: Unlike WBPET, the SUVmax in ring-type DbPET can represent the immune microenvironment after adjusting for tumor biological factors. DbPET might be a biomarker of pathological response to neoadjuvant chemotherapy and prognosis. Legal entity responsible for the study: Shinsuke Sasada. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
The real-world impact of modern treatments on the survival of patients with metastatic melanoma
Authors: M. Donia, E. Ellebaek, T.H. Øllegaard, L. Duval, J.B. Aaby, L. Højberg, U.H. Køhler, H. Schmidt, L. Bastholt, I.-M. Svane
Journal: Annals of Oncology (2018)
Long-term prognosis of acute pulmonary embolism: A focus on idiopathic and neoplastic etiologies
Authors: I.M.C. Guerreiro, H. Magalhães, S. Coelho, A.M. Ribeiro, S. Ferreira, E. Araújo, M. Fontes-Sousa, P. Bettencourt, P. Lourenço
Journal: Annals of Oncology (2018)
P1.11-11 Comparing Lung Cancer Diagnosed by Low Dose CT (LDCT), Incidental Lung Nodule Program (ILNP), and Non-Program-Based Detection
Authors: M. Smeltzer, N. Faris, J. Kethireddy, M. Meadows, M. Nalan, M. Ray, A. Epperson, D. Richards, K. Adams, A. Fulford, A. Wagh, J. Machin, K. Tonkin, R. Optican, J. Wright, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2018)
PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)
Authors: M.P. Ducreux, R. Desgrippes, M. Texier, F. Di Fiore, P. Vanelslander, O. Capitain, R. Guimbaud, J. Forestier, F. El Hajbi, P. Follana, A. Parzy, N. Baba Hamed, Y. Rinaldi, T. Brotelle, J.-P. Pignon, C. Jouffroy, L. Dahan, O. Bouche
Journal: Annals of Oncology (2018)
Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population
Authors: M.C.T. van Zeijl, M.W.J.M. Wouters, A.J. van den Eertwegh, M.J. Aarts, A.C.J. van Akkooi, F.W.P.J. van den Berkmortel, M.G. Franken, J.W.B. de Groot, K.H. Herbschleb, J.J.M. van der Hoeven, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. Ten Tije, A.A.M. Van der Veldt, G. Vreugdenhil, J.B.A.G. Haanen
Journal: Annals of Oncology (2018)
MA10.03 Plasmatic Evaluation of the Intestinal Barrier and Blood Microbiota, and Antibiotic Use in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Authors: J. Ouaknine, P. Helly De Tauriers, C. Dumenil, N. Neveux, J. Dumoulin, V. Giraud, S. Labrune, J. Tisserand, J. Emile, T. Chinet, E. Giroux Leprieur
Journal: Journal of Thoracic Oncology (2018)
FOLFIRINOX for recurrent pancreatic cancer after resection: Nationwide multicenter observational study by Japan adjuvant study group of pancreatic cancer (JASPAC)
Authors: S. Morinaga, M. Takita, A. Yoshizawa, K. Kamei, S. Nakamori, S. Ishihara, H. Kuramochi, Y. Yokoyama, T. Uchiyama, G. Murohisa, M. Kobayashi, A. Todaka, A. Fukutomi
Journal: Annals of Oncology (2018)
Human monocytes and macrophages regulate immune tolerance via integrin αvβ8–mediated TGFβ activation
Authors: Aoife Kelly, Sezin Gunaltay, Craig P. McEntee, Elinor E. Shuttleworth, Catherine Smedley, Stephanie A. Houston, Thomas M. Fenton, Scott Levison, Elizabeth R. Mann, Mark A. Travis
Journal: The Journal of Experimental Medicine (2018)

Monocytes are crucial immune cells involved in regulation of inflammation either directly or via differentiation into macrophages in tissues. However, many aspects of how their function is controlled in health and disease are not understood. Here we show that human blood monocytes activate high levels of the cytokine TGFβ, a pathway that is not evident in mouse monocytes. Human CD14
Abstract 18284: The Significant Improvement of Cardiac Function After Pulmonary Artery Denervation Procedure in Patients With Pulmonary Arterial Hypertension
Authors: Jing Ping Sun, Juan Zhang, Zuo Ying Hu, Yan Liu, Jiang Xie Du, Hang Zhang, Feng Fu Zhang, Bryan P Yan, Gregg W Stone, Shao-Liang Chen
Journal: Circulation (2016)

Background: Based on our preliminary experience with performing pulmonary artery denervation (PADN) on patients (pts) with idiopathic pulmonary arterial hypertension (IPAH), we started to perform P...